Oaktree Specialty Lending’s third quarter results were shaped by a significant year-over-year decline in revenue, which management attributed to subdued exit activity and continued pressure in certain portfolio sectors. Despite lower sales and a drop in GAAP profit, the company’s operating margin remained stable, and management focused on improving the quality of its loan portfolio. CEO Armen Panossian noted that the team made “tangible progress reducing nonaccruals and resolving challenged investments,” with nonaccruals falling to 2.8% of the portfolio. The market responded neutrally, reflecting a view that the results generally aligned with expectations and that operational execution was steady.

Is now the time to buy OCSL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Oaktree Specialty Lending’s Q3 Earnings Call

• Melissa Wedel (JPMorgan) asked about the outlook for investment activity and repayments in the next quarter. CEO Armen Panossian replied that no outsized repayments are expected and that deployment should be in line with previous periods, given current market conditions.
• Wedel (JPMorgan) also questioned the higher yield on new investments, specifically referencing the Walgreens deal. CFO Christopher McKown confirmed the yield increase was largely due to the complexity and risk premium of the Walgreens transaction, while Panossian noted such high-spread deals are unlikely to recur immediately.
• Sean Paul Adams (B. Riley Securities) inquired about the concentration of nonaccrual loans in healthcare and life sciences. Panossian explained that while these positions have weighed on nonaccruals, no new problematic loans have been added recently, and operational improvements are ongoing.
• Adams (B. Riley Securities) followed up on workout strategies for longstanding nonaccruals. Panossian detailed that these assets have already undergone capital structure restructuring, and the focus is now on operational turnarounds and asset sales when possible.
• No further analyst questions were asked on the call.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be monitoring (1) the pace and success of nonaccrual and equity position monetizations, (2) ongoing improvements in portfolio diversification and risk management, and (3) the ability to maintain or improve earnings power in the face of changing interest rates and competitive lending pressures. Developments in complex deal origination and joint venture performance will also serve as important indicators of execution.

Oaktree Specialty Lending currently trades at $13.61, up from $13.33 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

The Best Stocks for High-Quality Investors

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.